The concept of telemedicine has evolved in recent years. As people are demanding easier ways to avail of medical treatment and diagnosis, there have been several advances in telemedicine. Telemedicine […]readmore
On September 2, 2020, Octavus Consulting and DealForma will present their most recent data and trends on dealmaking across biopharma, device, diagnostics, and digital health. Healthcare and life sciences deal […]readmore
Shots: Cadalimab will be available in 40mg/0.8ml as a pre-filled syringe and is targeted for the reduction in signs and symptoms of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic […]readmore
The US FDA has approved multiple NDAs and BLAs in July 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and […]readmore
K. K. Consulting Services has conducted this survey by contacting around 2200 medical representatives across the India using google forms. Objective of Survey The purpose of this survey is to […]readmore
Shots: BIOEQ will sponsor the P-III study which will assess the FYB203 vs Eylea in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy, safety and immunogenicity. Additionally, […]readmore
Biosimilars
Regulatory
Samsung Bioepis’ Aybintio (SB8, biosimilar, bevacizumab) Receives the EC’s Approval
Shots: The EMA’s CHMP positive opinion was provided in June and is the fifth product which received the EU approval for autoimmune diseases and tumor diseases The P-III study results […]readmore
Shots: The two companies will work together to research, discover, and develop therapeutic options related to the deficiency of the protein GBA which is a gene linked to Gaucher disease […]readmore
Shots: The companies will use BioSymetrics Contingent-AI engine to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course and identify markers for clinical […]readmore
Biosimilars
Regulatory
Sandoz Canada Negotiated with Pan-Canadian Pharmaceutical Alliance (pCPA) to Launch
Shots: In Jul 2020, following the pCPA agreement Riximyo is now reimbursed through Limited Use as well as the Exceptional Access Program while funding will be done by Cancer Care […]readmore